Millipore Sigma Vibrant Logo

203811 Bryostatin 1 - CAS 83314-01-6 - Calbiochem

A macrocyclic lactone with antitumor properties.

Bryostatin 1 - CAS 83314-01-6 - Calbiochem: Ficha de datos de seguridad (MSDS o SDS), certificado de análisis y de calidad (CoA y CoQ), expedientes, folletos y otros documentos disponibles.

Sinónimos: Bryo 1, PKC Activator VII, PKC Activator VI

Primary Target: Protein kinase C
View Products on Sigmaaldrich.com
203811
Ver precios y disponibilidad

Descripción

Replacement Information

Tabla espec. clave

CAS #Empirical Formula
83314-01-6C₄₇H₆₈O₁₇

Precios y disponibilidad

Número de referencia DisponiblidadEmbalaje Cant./Env. Precio Cantidad
203811-10UG
Comprobando disponibilidad...
—
Disponibilidad a confirmar Disponibilidad a confirmar
Ingrese cantidad 
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    El resto: se avisará
      El resto: se avisará
      Se avisará
      Póngase en contacto con el Servicio de Atención al Cliente
      Contact Customer Service

      		 Ampolla de plást. 10 μg
      Recuperando precio...
      No pudo obtenerse el precio
      La cantidad mínima tiene que ser múltiplo de
      Maximum Quantity is
      Al finalizar el pedido Más información
      Ahorró ()
       
      —
      Solicitar precio
      		 —
      Description
      OverviewA macrocyclic lactone with antitumor properties. Potently activates protein kinase C and exhibits a high binding affinity (Ki = 1.35 nM). Effectively translocates and down-regulates PKC isozymes α, δ, and ε. Induces a biphasic activation of PKD through a PKC-dependent pathway in intact cells. Also shown to activate Ras in Jurkat T cells and in rat2 cells.
      Catalogue Number203811
      Brand Family Calbiochem®
      SynonymsBryo 1, PKC Activator VII, PKC Activator VI
      References
      ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
      Product Information
      CAS number83314-01-6
      ATP CompetitiveN
      FormWhite to colorless solid or film
      Hill FormulaC₄₇H₆₈O₁₇
      Chemical formulaC₄₇H₆₈O₁₇
      ReversibleN
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Primary TargetProtein kinase C
      Primary Target K<sub>i</sub>1.35 nM for protein kinase C
      Purity≥98% by HPLC
      Physicochemical Information
      Cell permeableN
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      RTECSEH9455000
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage -20°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      Número de referencia GTIN
      203811-10UG 04055977204025

      Documentation

      Bryostatin 1 - CAS 83314-01-6 - Calbiochem Ficha datos de seguridad (MSDS)

      Título

      Ficha técnica de seguridad del material (MSDS) 

      Bryostatin 1 - CAS 83314-01-6 - Calbiochem Certificados de análisis

      CargoNúmero de lote
      203811

      Referencias bibliográficas

      Visión general referencias
      Clamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.
      Ficha técnica

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision17-December-2018 JSW
      SynonymsBryo 1, PKC Activator VII, PKC Activator VI
      DescriptionA macrocyclic lactone that exhibits anti-tumor properties. Potently activates protein kinase C and exhibits high binding affinity (Ki = 1.35 nM). Effectively translocates protein kinase C (PKC) isozymes α, β, and ε and induces a biphasic, concentration-dependent, down-regulation of PKC δ. Reported to compete with phorbol esters in binding to PKC. Stimulates protein kinase D (PKD) activity in a biphasic, PKC-dependent manner in intact cells. Also activates Ras in Jurkat T cells and in rat2 cells.
      FormWhite to colorless solid or film
      CAS number83314-01-6
      RTECSEH9455000
      Chemical formulaC₄₇H₆₈O₁₇
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (25 mg/ml) or Ethanol (25 mg/ml)
      Storage Protect from light
      -20°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      Merck USA index14, 1457
      ReferencesClamp, A., and Jayson, G. 2002. Anticancer Drugs 13, 673.
      Lorenzo, P.S., et al. 1999. Cancer Res. 59, 6137.
      Wang, Q.J., et al. 1999. J. Biol. Chem. 274, 37233.
      Wender, P.A., et al. 1998. Proc. Natl. Acad. Sci. USA 95, 6624.
      Matthews, S.A., et al. 1997. J. Biol. Chem. 272, 20245.
      Szallasi, Z., et al. 1994. Mol. Pharmacol. 46, 840.
      Berkow, R.L., and Kratt, A.S. 1985. Biochem. Biophys. Res. Commun. 3, 1109.